Discovery Genomics, Inc.

Website Links

Description

AngioGenetics is a Swedish drug-discovery company focusing on angiogenesis, the formation of new blood vessels. The company, based in Gothenburg, was incorporated in June 2001 as a spin-out from Gothenburg University and the Karolinska Institute. The focus of AngioGenetics is early drug discovery in the area of angiogenesis regulation, with the aim of developing drugs for diseases in which angiogenesis is central to the pathology.

Discovery Genomics, Inc. (DGI) is an early stage biotechnology company focused on providing gene therapy for the treatment of inherited and acquired blood diseases. DGI has raised $4 million through private and institutional investors. TECHNE Corporation ( http://www.techne-corp.com ) led our first round of financing in 2001.

Discovery Genomics, Inc. (DGI) was founded in 2000 and became operational in January 2002. DGI maintains exclusive rights to two breakthrough technologies that significantly enhance the development of new therapeutics ? from gene discovery to treatment delivery.

Founded in 2000, Discovery Genomics, Inc. (DGI) began operations in January 2002. We discover gene functions and deliver safe, long-lasting gene therapy.

The technology?s feasibility and value is evidenced through DGI?s discoveries and service relationships. DGI has discovered 15 genes and partially validated and filed patents on six genes related to angiogenesis and bone and cartilage formation. We provide gene function assessment and/or compound evaluation services to major pharmaceutical clients.

Products & services

Similar companies nearby